Index -
P/E -
EPS (ttm) -1.60
Insider Own 1.52%
Shs Outstand 240.40M
Perf Week -2.82%
Market Cap 23.60B
Forward P/E -
EPS next Y -4.34
Insider Trans 0.00%
Shs Float 236.74M
Perf Month -12.79%
Enterprise Value 7.88B
PEG -
EPS next Q -1.22
Inst Own 22.01%
Short Float 2.54%
Perf Quarter -6.50%
Income -381.72M
P/S 7.55
EPS this Y -74.34%
Inst Trans 3.40%
Short Ratio 7.28
Perf Half Y -0.82%
Sales 3.13B
P/B 1.09
EPS next Y 23.93%
ROA -1.55%
Short Interest 6.02M
Perf YTD -13.87%
Book/sh 90.36
P/C 1.47
EPS next 5Y -12.60%
ROE -1.81%
52W High 131.49 -25.36%
Perf Year -20.46%
Cash/sh 66.69
P/FCF -
EPS past 3/5Y - -25.87%
ROIC -1.74%
52W Low 81.20 20.87%
Perf 3Y -33.80%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y -49.00% 89.57%
Gross Margin 79.80%
Volatility 5.23% 3.67%
Perf 5Y 62.52%
Dividend TTM -
EV/Sales 2.52
EPS Y/Y TTM 30.53%
Oper. Margin -18.52%
ATR (14) 4.21
Perf 10Y -
Dividend Ex-Date Jun 02, 2022
Quick Ratio 8.48
Sales Y/Y TTM 7.51%
Profit Margin -12.21%
RSI (14) 40.46
Recom 1.61
Dividend Gr. 3/5Y - -
Current Ratio 8.61
EPS Q/Q 50.13%
SMA20 -5.02%
Beta 1.46
Target Price 141.30
Payout -
Debt/Eq 0.01
Sales Q/Q 113.52%
SMA50 -9.34%
Rel Volume 1.25
Prev Close 99.26
Employees 6772
LT Debt/Eq 0.01
Earnings Aug 04 BMO
SMA200 -9.18%
Avg Volume 826.29K
Price 98.15
IPO Oct 10, 2019
Option/Short Yes / Yes
EPS/Sales Surpr. 28.90% 70.34%
Trades
Volume 1,034,006
Change -1.12%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-05-25 Reiterated
H.C. Wainwright
Buy
$134 → $145
May-29-25 Initiated
Goldman
Neutral
$110
Mar-13-25 Initiated
Citigroup
Buy
$145
Jan-10-25 Initiated
Truist
Buy
$172
Dec-11-24 Initiated
Wells Fargo
Overweight
$170
Dec-02-24 Reiterated
BMO Capital Markets
Outperform
Nov-19-24 Upgrade
Evercore ISI
In-line → Outperform
$110 → $125
Nov-19-24 Initiated
Berenberg
Buy
$130
Nov-08-24 Upgrade
Goldman
Neutral → Buy
$90 → $137
Sep-24-24 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$93 → $145
Sep-17-24 Upgrade
Jefferies
Hold → Buy
$96 → $150
Sep-16-24 Upgrade
JP Morgan
Underweight → Neutral
$91 → $125
Aug-07-24 Upgrade
Deutsche Bank
Hold → Buy
$95
Aug-02-24 Upgrade
HSBC Securities
Hold → Buy
May-14-24 Initiated
Evercore ISI
In-line
$100
Feb-23-24 Initiated
BMO Capital Markets
Outperform
$127
Jan-05-24 Initiated
Oppenheimer
Perform
Dec-01-23 Downgrade
JP Morgan
Neutral → Underweight
$106 → $99
Oct-16-23 Downgrade
HSBC Securities
Buy → Hold
$124 → $111
Jul-14-23 Initiated
HSBC Securities
Buy
$124
Show Previous Ratings
Sep-17-25 10:04AM
Sep-15-25 08:56AM
04:00AM
Sep-14-25 01:16AM
Sep-13-25 01:56PM
07:43PM
Loading…
Sep-12-25 07:43PM
06:19PM
04:21PM
(The Wall Street Journal)
02:11PM
(The Wall Street Journal)
01:37PM
12:33PM
12:11PM
11:35AM
09:08AM
Sep-11-25 01:01PM
09:52AM
Loading…
09:52AM
Sep-09-25 01:17PM
Sep-08-25 06:12PM
04:08PM
(Investor's Business Daily)
01:41PM
11:26AM
11:00AM
06:45AM
Sep-05-25 04:41PM
01:46PM
12:22PM
10:27AM
(Investor's Business Daily)
09:27AM
(Investor's Business Daily)
09:09AM
Aug-31-25 08:40AM
07:55AM
Loading…
Aug-28-25 07:55AM
(Pharmaceutical Technology)
04:53AM
Aug-27-25 02:30PM
(Investor's Business Daily)
01:42PM
(The Wall Street Journal)
12:50PM
Aug-26-25 08:31PM
Aug-11-25 05:15AM
04:19AM
Aug-08-25 07:54AM
04:01AM
03:31AM
(The Wall Street Journal)
Aug-06-25 09:18AM
Aug-05-25 11:55AM
11:47AM
06:00AM
03:00AM
Aug-04-25 11:16PM
08:51AM
07:01AM
06:51AM
06:45AM
Aug-03-25 02:00PM
Aug-01-25 01:21PM
11:23AM
10:01AM
08:44AM
Jul-31-25 12:18PM
11:43AM
10:42AM
08:57AM
07:57AM
(The Wall Street Journal)
07:48AM
07:01AM
Jul-30-25 12:00PM
11:07AM
04:31AM
Jul-29-25 10:00AM
08:26AM
06:52AM
Jul-28-25 09:28AM
Jul-25-25 07:36AM
02:30AM
Jul-24-25 10:49AM
09:40AM
Jul-23-25 10:14AM
Jul-21-25 06:45AM
Jul-18-25 06:20AM
(Pharmaceutical Technology)
Jul-17-25 08:30AM
Jul-16-25 08:41AM
Jul-11-25 10:58AM
Jul-09-25 10:30AM
Jul-07-25 07:17AM
Jul-04-25 09:00AM
(The Wall Street Journal)
Jun-30-25 09:50AM
Jun-20-25 11:51AM
Jun-13-25 12:15PM
08:16AM
Jun-12-25 12:49PM
(Pharmaceutical Technology)
12:11PM
10:25AM
10:20AM
09:15AM
07:51AM
(The Wall Street Journal)
07:44AM
07:18AM
(The Wall Street Journal)
07:11AM
06:58AM
06:45AM
Jun-11-25 10:20AM
Jun-10-25 04:10PM
(Investor's Business Daily)
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ATHOS KG 10% Owner Sep 05 '25 Proposed Sale 112.46 500,000 56,230,000 Sep 05 04:41 PM Medine GmbH Officer Aug 15 '25 Proposed Sale 112.70 1,774,837 200,024,130 Aug 15 08:27 AM Tureci Ozlem Officer Aug 15 '25 Proposed Sale 112.70 185,001 20,849,613 Aug 15 08:22 AM Jeggle Helmut Wolfgang Director Jun 04 '25 Proposed Sale 113.10 150,000 16,965,000 Jun 04 08:31 AM ATHOS KG 10% Owner Jun 02 '25 Proposed Sale 110.83 175,000 19,394,800 Jun 02 04:08 PM ATHOS KG 10% Owner May 28 '25 Proposed Sale 98.68 500,000 49,340,000 May 28 09:00 AM Jeggle Helmut Wolfgang Director May 07 '25 Proposed Sale 94.74 150,000 14,211,000 May 07 07:30 AM Richardson Ryan Officer Feb 27 '25 Proposed Sale 114.00 26,500 3,021,000 Feb 27 07:57 AM Medine GmbH Officer Feb 20 '25 Proposed Sale 119.58 1,000,000 119,580,000 Feb 20 07:53 AM Poetting Sierk Officer Feb 20 '25 Proposed Sale 119.58 120,000 14,349,600 Feb 20 07:50 AM ATHOS KG 10% Owner Dec 13 '24 Proposed Sale 120.69 4,983 601,398 Dec 13 05:56 PM ATHOS KG 10% Owner Dec 11 '24 Proposed Sale 116.85 22,450 2,623,283 Dec 11 05:25 PM ATHOS KG 10% Owner Dec 09 '24 Proposed Sale 121.72 53,716 6,538,312 Dec 09 06:35 PM ATHOS KG 10% Owner Dec 06 '24 Proposed Sale 118.84 13,104 1,557,279 Dec 06 05:57 PM ATHOS KG 10% Owner Nov 27 '24 Proposed Sale 118.54 44,374 5,260,094 Nov 27 05:50 PM ATHOS KG 10% Owner Nov 26 '24 Proposed Sale 120.76 10,000 1,207,600 Nov 26 06:37 PM ATHOS KG 10% Owner Nov 25 '24 Proposed Sale 113.13 75,000 8,484,750 Nov 25 05:06 PM Jeggle Helmut Wolfgang Director Nov 15 '24 Proposed Sale 103.56 150,000 15,534,000 Nov 15 05:12 PM Tureci Ozlem Officer Nov 12 '24 Proposed Sale 108.73 556,000 60,453,880 Nov 12 07:39 AM ATHOS KG 10% Owner Oct 16 '24 Proposed Sale 117.74 8,036 946,154 Oct 16 05:03 PM ATHOS KG 10% Owner Oct 14 '24 Proposed Sale 120.83 25,424 3,071,964 Oct 15 08:41 AM ATHOS KG 10% Owner Oct 11 '24 Proposed Sale 120.13 40,000 4,805,228 Oct 11 04:15 PM ATHOS KG 10% Owner Oct 10 '24 Proposed Sale 117.47 20,000 2,349,436 Oct 10 04:13 PM ATHOS KG 10% Owner Oct 09 '24 Proposed Sale 119.06 6,000 714,361 Oct 09 04:02 PM ATHOS KG 10% Owner Oct 08 '24 Proposed Sale 122.01 15,000 1,830,100 Oct 08 04:24 PM ATHOS KG 10% Owner Oct 04 '24 Proposed Sale 122.80 14,756 1,812,078 Oct 04 04:17 PM ATHOS KG 10% Owner Oct 03 '24 Proposed Sale 119.27 50,000 5,963,585 Oct 03 05:14 PM ATHOS KG 10% Owner Oct 02 '24 Proposed Sale 119.04 65,200 7,761,193 Oct 02 06:18 PM ATHOS KG 10% Owner Oct 01 '24 Proposed Sale 119.24 72,086 8,595,657 Oct 01 04:18 PM ATHOS KG 10% Owner Sep 30 '24 Proposed Sale 118.22 76,114 8,998,197 Sep 30 04:52 PM ATHOS KG 10% Owner Sep 27 '24 Proposed Sale 117.64 37,204 4,376,679 Sep 27 05:12 PM ATHOS KG 10% Owner Sep 25 '24 Proposed Sale 118.47 37,943 4,495,107 Sep 25 07:14 PM